A recombinant human IL-18-binding protein (IL-18BP, Tadekinig Alfa), an endogenous antagonist of IL-18, is also in mid-late phase clinical trials for AOSD, XIAP deficiency and NLRC4-MAS38–40. The gene discussed is NLRC4; the disease is adult-onset Still disease.